A Phase 1 interventional study of Elinzanetant (BAY3427080) and Placebo to elinzanetant in Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men and Hot Flashes, sponsored by Bayer. Completed at 1 site in Canada. Open to female participants aged 40 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-05-08.
Sponsored by Bayer · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing elinzanetant in Hot Flashes — none open to participants now, 1 under way, 1 of them phase 3. elinzanetant · Hot Flashes.
Among the 13 studies testing elinzanetant in Hot Flashes, this one is the 7th largest by enrollment, is the only one that started in 2024, is one of 7 in phase 1, and was the 13th registered.
339 studies on the registry are indexed under Hot Flashes; 56 are open to participants now.
Browse Hot Flashes studies →None of the 13 studies testing elinzanetant in Hot Flashes is open now. The open studies under Hot Flashes, anywhere →
elinzanetant: first FDA approval 2025 (LYNKUET), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →
Of the 36 Hot Flashes studies recruiting now, 13 (36%) set no upper age limit and 21 (58%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.
This study: 40 Years to 65 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 2 · Phase 3 4
First in 2016; this study’s year is marked. 1 started in 2024.
This study's enrollment of 64 is below the median of 90 across 306 interventional studies indexed under Hot Flashes.
Median enrollment 64 across the 13 interventional studies. Of the 12 that completed or were terminated, 5 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 13 have an industry lead sponsor. The 1 most frequent:
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
18 studies in Hot Flashes by Bayer: none open now, 1 under way, 1 of them phase 3. Of 17 finished, 7 (41%) have results posted.
Among the 18 studies in Hot Flashes by Bayer, this one is the 12th largest by enrollment, is the only one that started in 2024, is one of 7 in phase 1, and was the 18th registered.
Bayer’s Hot Flashes studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 13 studies testing elinzanetant in Hot Flashes, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Bayer’s 18 in Hot Flashes:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Researchers are looking for a better way to treat vasomotor symptoms (VMS), also known as hot flashes.
Hot flashes are intense and sudden feelings of heat along with sweating and reddening of the skin. These are common for women going through the menopause but can also occur in men. Such symptoms are called VMS and are caused by changes in sex hormone levels.
The study treatment, elinzanetant, is being tested for the treatment of VMS in both men and women. It works by blocking the activity of a substance called neurokinin, which is thought to play a role in starting hot flashes.
Elinzanetant may cause lasting effects like sleepiness and tiredness. Such effects may make driving unsafe.
The main purpose of this study is to learn how elinzanetant affects the ability to drive the next day in healthy women.
For this, researchers will study participants' ability to keep a stable position within their lane while driving on a straight road on a computer-based driving test (also known as a driving simulator).
In this study, participants will take 2 different doses of elinzanetant, another drug called zopiclone, and matching placebos to these drugs.
Zopiclone helps treat sleeping problems. A placebo looks like a study drug but does not have any medicine in it.
Participants will take elinzanetant, zopiclone, and their matching placebos by mouth.
This study will have 4 treatment periods with each period lasting 6 days. In each period, participants will receive one of the following treatments in an order assigned to them randomly (by chance):
Each participant will be in the study for around 15 weeks with up to 6 visits to the study site.
Participants will visit the study site:
During the study, the doctors and their study team will:
An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events, irrespective of whether they think they are related to the study treatment or not.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Treatment A (elinzanetant dose A). Treatment B (elinzanetant dose B). Treatment C (zopiclone 7.5 mg). Treatment D (placebo).
Drug: Elinzanetant (BAY3427080) · Drug: Placebo to elinzanetant · Drug: Zopiclone · Drug: Placebo to zopiclone
Treatment A (elinzanetant dose A). Treatment B (elinzanetant dose B). Treatment C (zopiclone 7.5 mg). Treatment D (placebo).
Drug: Elinzanetant (BAY3427080) · Drug: Placebo to elinzanetant · Drug: Zopiclone · Drug: Placebo to zopiclone
Treatment A (elinzanetant dose A). Treatment B (elinzanetant dose B). Treatment C (zopiclone 7.5 mg). Treatment D (placebo).
Drug: Elinzanetant (BAY3427080) · Drug: Placebo to elinzanetant · Drug: Zopiclone · Drug: Placebo to zopiclone
Treatment A (elinzanetant dose A). Treatment B (elinzanetant dose B). Treatment C (zopiclone 7.5 mg). Treatment D (placebo).).
Drug: Elinzanetant (BAY3427080) · Drug: Placebo to elinzanetant · Drug: Zopiclone · Drug: Placebo to zopiclone
Oral administration of multiple doses of elinzanetant.
Oral administration
Oral administration
Oral administration
Simulated driving performance as measured by SDLP using CRCDS-MiniSim
SDLP: standard deviation of lateral position. CRCDS-MiniSim: Cognitive Research Corporation's Driving Simulator-MiniSim.
Time frame: Approximately 9 hours after last dose
Lane Exceedance: Number of Exceedance.
Time frame: Approximately 9 hours after last dose
Lane Exceedance: Maximum Duration of Exceedance.
Time frame: Approximately 9 hours after last dose
Lane Exceedance: Area of Exceedance.
Time frame: Approximately 9 hours after last dose
Excessive Speed Count
Time frame: Approximately 9 hours after last dose
Average Speed and Speed Deviation
Time frame: Approximately 9 hours after last dose
Driving safety measures: Total number of excessive Ay (cornering speed threshold-exceeded)
Time frame: Approximately 9 hours after last dose
Driving safety measures: Total number of collisions
Time frame: Approximately 9 hours after last dose
Divided Attention: Correct responses; Omission Errors; Commission Errors; Reaction Time; Standard Deviation of Reaction Time
Time frame: Approximately 9 hours after last dose
CogScreen Symbol Digit Coding Test: Number of Correct responses
CogScreen Symbol Digit Coding test is a computer analogue of the conventional digit symbol-substitution task found in the revised Wechsler intelligence scales.
Time frame: Approximately 9 hours after last dose
CogScreen Symbol Digit Coding Test: Response Accuracy (percentage of correct responses)
Time frame: Approximately 9 hours after last dose
CogScreen Symbol Digit Coding Test: Standard Deviation of Reaction Time
Time frame: Approximately 9 hours after last dose
Karolinska Sleepiness Scale (KSS) Score
The KSS measures an individual's subjective level of sleepiness. Participants indicate their level of alertness versus sleepiness according to a 9-point scale, ranging from "extremely alert" to "extremely sleepy - fighting sleep".
Time frame: Approximately 9 hours after last dose
Participant's self-reported Readiness to Drive
Prior to driving, the participant will be asked a simple question as to whether they feel safe to drive ("Right now do you feel safe to drive?"). Participant will answer "yes" or "no".
Time frame: Approximately 9 hours after last dose
Self-report of motivation and appraisal of driving performance using VAS
Participants will record their response to each question by drawing a vertical line on a 100-mm horizontal, linear VAS printed on paper. For the self-assessment of driving performance, one end of the line is marked "Not Satisfactory" and the other end of the line is marked "Satisfactory". For the motivation item, 1 end of the line is marked "Not Motivated" and the other end is marked "Motivated". Scores on the 100-mm linear scale will be measured to the nearest millimeter from the left with a ruler.
Time frame: Approximately 9 hours after last dose
Plan to share: No — Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.
Ran from Jan 2024 to primary completion in Apr 2024, 3 months.
Of 10 phase 1 interventional studies under Hot Flashes, half reached primary completion within 3 months of starting (the median); a quarter within 1 and three quarters within 9. This study's 3 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Elinzanetant